LONDON, Nov. 15, 2010 /PRNewswire/ -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announced the launch of Chiltern SAFE.
"Chiltern SAFE is revolutionizing records management for clinical trials, stated Sarah Hitching, Chiltern Director, Records Management. "This complete electronic Trial Master File (TMF) solution facilitates remote management of documents, which saves administrative time and increases accuracy and security of records handling. It has many great features, all with integrated quality controls such as a unique duplicate document warning system and tracking of expected and missing documents as well as electronic submission of documents that do not require original signatures. Features like these ensure the process delivers the highest compliance and quality possible, with the greatest level of efficiencies. In addition, Chiltern SAFE is able to handle a wide range of metadata and is able to record whether a document on file is the original or a copy. We are also proud to announce that this system is fully validated and compliant with 21 CFR part 11 and other regulations."
Stuart Young, Chiltern Executive Vice President, Global Clinical Monitoring, added, "We offer Chiltern SAFE as a standalone service or as part of our full clinical trial service package and for future or historic studies. Another distinct advantage of Chiltern SAFE is our dedicated records management (RM) team on site at each of our three data repositories globally: Germany, UK and USA. This team of TMF experts work in partnership with our clients to guide users through Chiltern SAFE, thus ensuring the system is not only "SAFE", but also effective and user-friendly."
Glenn Kerkhof, Chiltern CEO, commented, "Chiltern SAFE is a comprehensive global TMF management solution designed to centrally control, track and maintain all study-related documentation. Its capabilities allow quick document search and retrieval as well as instant access to real time reports, user activities and study information."
Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern has conducted trials in more than 40 countries, has 24 offices and legal entities within 20 countries, resources in 37 countries and employs nearly 1,400 people globally. Chiltern provides Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions services. Further information: www.chiltern.com.
For More Information Contact:
Natalie Chong, Marketing Director
Susan Ojanen, Marketing Associate
Chiltern International Ltd.
Chiltern International Inc.
171 Bath Road
1241 Volunteer Parkway
Berkshire SL1 4AA
Bristol, TN 37620
Tel: +44 (0) 1753 512 000
Tel: +1 (423) 968 9533
Fax: +44 (0) 1753 511 116
Fax: +1 (423) 968 3567